Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy (IGNAZ)
Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy (IGNAZ)
Randomized, placebo-controlled, multi-center, double-blind, proof of concept phase IIa trial and dose evaluation trial of felzartamab in IgAN
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 48 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double Blind, Randomized, Placebo-Controlled, Multicenter Phase IIa, Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab in IgA Nephropathy
Actual Study Start Date: August 31, 2021
Estimated Primary Completion Date: January 2023
Estimated Study Completion Date: January 2024
Arm:
- Placebo Comparator: Placebo
- Experimental: Felzartamab Arm #1
- Experimental: Felzartamab Arm #2
- Experimental: Felzartamab Arm #3
| Category | Value |
|---|---|
| Study type(s) | Interventional |
| Estimated enrolment | 48 |
| Actual Study start date | 31 August 2021 |
| Estimated Study Completion Date | 01 January 2024 |